What is Testro AQ?
Testro AQ is a naturally occurring sex hormone produced in a man's testicles. Small amounts of Testro AQ are also produced in a woman's ovaries and adrenal system.
Testro AQ is used in men and boys to treat conditions caused by a lack of this hormone, such as delayed puberty, impotence, or other hormonal imbalances. This medicine is not for use in treating low Testro AQ without certain medical conditions or due to getting older.
Testro AQ enanthate is used in women to treat breast cancer that has spread to other parts of the body (metastatic) and cannot be treated with surgery.
Testro AQ will not enhance athletic performance and should not be used for that purpose.
Testro AQ may also be used for purposes not listed in this medication guide.
Testro AQ indications
Testro AQ Gel 1% is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous Testro AQ:
- Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum Testro AQ concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
- Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low Testro AQ serum concentrations, but have gonadotropins in the normal or low range.
Limitations of use:
- Safety and efficacy of Testro AQ Gel 1% in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established.
- Safety and efficacy of Testro AQ Gel 1% in males less than 18 years old have not been established.
Topical Testro AQ products may have different doses, strengths or application instructions that may result in different systemic exposure (1, 12.3).
How should I use Testro AQ?
Use Testro AQ solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Testro AQ solution comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Testro AQ solution refilled.
- Prime this product before the first use. To prime it, depress the pump 3 times and wash any product that is dispensed down the sink.
- Depress the pump once to fill the applicator cup. Holding the applicator upright, wipe Testro AQ solution steadily up and down onto clean, dry skin in the armpit. If Testro AQ solution drips or runs, it can be wiped back up with the applicator cup. Do NOT apply Testro AQ solution to other parts of your body (eg, scrotum, penis, stomach, shoulders, upper arms). Do NOT apply it over open sores, wounds, or irritated skin.
- Do NOT use your fingers or hand to rub the medicine into the skin.
- You may need to alternate between armpits when applying Testro AQ solution. Be sure you understand how to apply Testro AQ solution. Contact your doctor or pharmacist if you have questions or concerns about how to apply Testro AQ solution.
- Wash your hands with soap and water immediately after using Testro AQ solution.
- Allow Testro AQ solution to dry completely before dressing.
- After Testro AQ solution has dried, cover the application site (eg, with a shirt) to prevent others from coming into contact with Testro AQ solution. If direct skin-to-skin contact with another person is expected, wash the application site well with soap and water to remove the medicine.
- After using Testro AQ solution, rinse the applicator with room temperature water and pat it dry with a tissue. Replace the applicator and cap on the bottle for storage.
- Do NOT get Testro AQ solution in your eyes. If you do, rinse thoroughly with water. If eye irritation persists, contact your doctor.
- Apply Testro AQ solution at the same time every morning after showering or bathing, unless your doctor tells you otherwise.
- If you are also using an antiperspirant or deodorant (stick or roll-on), apply it at least 2 minutes before you apply Testro AQ solution.
- For best results, wait 2 hours after applying Testro AQ solution before you wash the application site or swim.
- If you miss a dose of Testro AQ solution, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Testro AQ solution.
Uses of Testro AQ in details
Testro AQ is a male hormone primarily used to treat deficiency or absence of naturally produced hormone Testro AQ in men (hypogonadal disorders). The conditions include,
- Testicular diseases (primary hypogonadism) - diseases or conditions of testes, the organ that produces Testro AQ affecting secretion of Testro AQ.
- Pituitary diseases (secondary hypogonadism) - diseases or conditions of pituitary gland or hypothalamus that produce hormones (gonadotropins) which stimulate release of Testro AQ.
Testro AQ description
Testro AQ is a steroid sex hormone found in both men and women. In men, Testro AQ is produced primarily by the Leydig (interstitial) cells of the testes when stimulated by luteinizing hormone (LH). It functions to stimulate spermatogenesis, promote physical and functional maturation of spermatozoa, maintain accessory organs of the male reproductive tract, support development of secondary sexual characteristics, stimulate growth and metabolism throughout the body and influence brain development by stimulating sexual behaviors and sexual drive. In women, Testro AQ is produced by the ovaries (25%), adrenals (25%) and via peripheral conversion from androstenedione (50%). Testerone in women functions to maintain libido and general wellbeing. Testro AQ exerts a negative feedback mechanism on pituitary release of LH and follicle-stimulating hormone (FSH). Testro AQ may be further converted to dihydrotestosterone or estradiol depending on the tissue.
Testro AQ dosage
Testro AQ (Testro AQ (transdermal)) TTS
One system is applied at about the same time each day. The adhesive side of the Testro AQ (Testro AQ (transdermal)) TTS system should be placed on a clean, dry area of skin on the arm, back or upper buttocks immediately upon removal from the protective pouch. DO NOT APPLY TO THE SCROTUM. The area selected should not be oily, damaged, or irritated. The system should be pressed firmly in place with the palm of the hand for about 10 seconds, making sure there is good contact, especially around the edges. In the event that a system should fall off, the same system may be reapplied. If the system comes off after it has been worn for more than 12 hours and it cannot be reapplied, a new system may be applied at the next routine application time. In either case, the daily treatment schedule should be continued. The Testro AQ (Testro AQ (transdermal)) TTS system should be worn approximately 24 hours and then replaced. To ensure proper dosing, serum Testro AQ concentration may be measured 2-4 hours after an application of Testro AQ (Testro AQ (transdermal)) TTS. If the serum Testro AQ concentrations are low, the dosing regimen may be increased to 2 systems. Because of variability in analytical values among diagnostic laboratories, all Testro AQ measurements should be performed at the same laboratory.
Testro AQ (Testro AQ (transdermal)) and Testro AQ (Testro AQ (transdermal)) WITH ADHESIVE
Patients should start therapy with a 6 mg/d system of either Testro AQ (Testro AQ (transdermal)) or Testro AQ (Testro AQ (transdermal)) WITH ADHESIVE applied daily; if the scrotal area cannot accommodate a 6 mg/d system, a 4 mg/d Testro AQ (Testro AQ (transdermal)) system should be used. One Testro AQ (Testro AQ (transdermal)) or Testro AQ (Testro AQ (transdermal)) WITH ADHESIVE system should be placed on clean, dry, scrotal skin. Scrotal hair should be dry-shaved for optimal skin contact. Chemical depilatories should not be used. Testro AQ (Testro AQ (transdermal)) or Testro AQ (Testro AQ (transdermal)) WITH ADHESIVE should be worn 22-24 hours.
After 3-4 weeks of daily system use, blood should be drawn 2-4 hours after system application for determination of serum total Testro AQ. Because of variability in analytical values among diagnostic laboratories, this laboratory work and later analyses for assessing the effect of the Testro AQ (Testro AQ (transdermal)) and Testro AQ (Testro AQ (transdermal)) WITH ADHESIVE therapy should be performed at the same laboratory.
If patients have not achieved desired results by the end of 6-8 weeks of treatment with any of the Testro AQ (Testro AQ (transdermal)) products, another form of Testro AQ replacement therapy should be considered.
How supplied
Testro AQ (Testro AQ (transdermal)) TTS, Testro AQ (Testro AQ (transdermal)), and Testro AQ (Testro AQ (transdermal)) WITH ADHESIVE Testro AQ transdermal systems contain a Schedule III controlled substance as defined by the Anabolic Steroids Control Act.
Testro AQ (Testro AQ (transdermal)) TTS
Testro AQ (Testro AQ (transdermal)) TTS systems are supplied as individually pouched systems, 30 per carton. Testro AQ (Testro AQ (transdermal)) TTS 5 mg/d (Testro AQ Transdermal System) -- each 60 cm2 system contains 328 mg Testro AQ USP for nominal dose of 5 mg/day
Carton of 30 Testro AQ (Testro AQ (transdermal)) TTS 5 mg/d systemsNDC 17314-4717-3
Testro AQ (Testro AQ (transdermal)) and Testro AQ (Testro AQ (transdermal)) WITH ADHESIVE
Testro AQ (Testro AQ (transdermal)) and Testro AQ (Testro AQ (transdermal)) WITH ADHESIVE systems are supplied as individually pouched systems, 30 per carton.
Testro AQ (Testro AQ (transdermal)) 4 mg/d (Testro AQ Transdermal System) -- each 40 cm2 system contains 10 mg Testro AQ USP for nominal delivery of 4 mg for one day.
Carton of 30 Testro AQ (Testro AQ (transdermal)) 4 mg/d systems. NDC 17314-4608-3
Testro AQ (Testro AQ (transdermal)) and Testro AQ (Testro AQ (transdermal)) WITH ADHESIVE
6 mg/d (Testro AQ Transdermal System) -- each 60 cm2 system contains 15 mg Testro AQ USP for nominal delivery of 6 mg for one day.
Carton of 30 Testro AQ (Testro AQ (transdermal)) 6 mg/d systems. NDC 17314-4609-3
Carton of 30 Testro AQ (Testro AQ (transdermal)) WITH ADHESIVE 6 mg/d systemsNDC 17314-2836-3
Storage
Testro AQ (Testro AQ (transdermal)) TTS
Store at controlled room temperature below 25oC (77oF).
Testro AQ (Testro AQ (transdermal)) and Testro AQ (Testro AQ (transdermal)) WITH ADHESIVE
Store at room temperature 15-30oC (59-86oF).
Disposal
Testro AQ (Testro AQ (transdermal)) products should be discarded in household trash in a manner that prevents accidental application or ingestion by children or pets.
Caution: Federal law prohibits dispensing without prescription.
REFERENCE
1. Matsumoto AM, Sandblom RE, Schoene RB et al. Testro AQ replacement in hypogonadal men: Effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin Endocrinol (1985) 22: 713-721.
2. Schneider BK, Pickett CK, Zwillich CW et al. Influence of Testro AQ on breathing during sleep. J Appl Physiol (1986) 61: 618-623.
3. Matsumoto AM. Hormonal therapy of male hypogonadism. Endocrinol Metab Clin North Am. (1994) 23: 857-875.
4. Bardin CW, Swerdloff RS, Santen RJ. Androgens: Risks and benefits. J Clin Endocinol Metab (1991) 73: 4-7.
5. Nieschlag E, Wang CCL. Guidelines for the use of androgens in men. Geneva: World Health Organization (1992); 1-16.
6. Walle T, Walle UK, Mathur RS et al. Propranolol metabolism in normal subjects: Association with sex steroid hormones. Curr Pharmacol Ther (1994) 56:127-132.
7. Physicians Generic Rx: The Complete Drug Reference. (1996); II-1972
Testro AQ interactions
See also:
What other drugs will affect Testro AQ?
Drug Interactions
Anticoagulants: C-17 substituted derivatives of Testro AQ, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. Patients receiving oral anticoagulant therapy require close monitoring, especially when androgens are started or stopped.
Oxyphenbutazone: Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.
Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.
Propranolol: In a published pharmacokinetic study of an injectable Testro AQ product, administration of Testro AQ cypionate led to an increased clearance of propranolol in the majority of men tested.6
Corticosteroids: The concurrent administration of Testro AQ with ACTH or corticosteroids may enhance edema formation; thus these drugs should be administered cautiously, particularly in patients with cardiac or hepatic disease.7
Drug/Laboratory Test Interactions
Androgens may decrease levels of thyroxin-binding globulin, resulting in decreased total T. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.
The Testro AQ (Testro AQ (transdermal)) products contain a Schedule III controlled substance as defined by the Anabolic Steroids Control Act.
Testro AQ (Testro AQ (transdermal)) TTS is designed for application to arm, back or upper buttocks skin.
Testro AQ (Testro AQ (transdermal)) and Testro AQ (Testro AQ (transdermal)) WITH ADHESIVE are designed for application to scrotal skin only. Because scrotal skin is at least five times more permeable to Testro AQ than other skin sites, Testro AQ (Testro AQ (transdermal)) or Testro AQ (Testro AQ (transdermal)) WITH ADHESIVE will not produce adequate serum Testro AQ concentrations if applied to non-scrotal skin.
Ingestion of Testro AQ, or the contents of any of the Testro AQ (Testro AQ (transdermal)) products will not result in clinically significant serum Testro AQ concentrations due to extensive first-pass metabolism. In addition, an intramuscular injection of Testro AQ from any of the Testro AQ (Testro AQ (transdermal)) products will not produce adequate serum Testro AQ levels due to its short half-life (about 10 minutes).
Testro AQ side effects
See also:
What are the possible side effects of Testro AQ?
Adverse events are reported in this section by product. Adverse events reported during use of a given product may occur in patients who are treated with any Testro AQ (Testro AQ (transdermal)) product.
Adverse Events with Testro AQ (Testro AQ (transdermal)) TTS
In clinical studies of 457 participants (116 hypogonadal males and 341 healthy adult males) treated for up to 6 weeks with Testro AQ (Testro AQ (transdermal)) TTS, the most commonly reported adverse events were application site reactions of transient itching (12%) and moderate or severe erythema (3%).
Adverse events reported by less than 1% of Testro AQ (Testro AQ (transdermal)) TTS users in clinical trials that were of probable or unknown relationship to drug were:
Topical Reactions
Of 457 study participants, 3 men (1%) discontinued prematurely because of application site reactions.
There were no clinically significant differences in skin tolerability in younger (<65 years old) and older (³ 65 years old) subjects.
A contact sensitization rate of 0.5% for Testro AQ (Testro AQ (transdermal)) TTS was observed in a 6-week study of 233 normal male volunteers.
In one study with 14 days of daily use, 42% of patients reported 3 or more detachments of their Testro AQ (Testro AQ (transdermal)) TTS; of these detachments, 33% occurred during exercise.
Adverse Events with Testro AQ (Testro AQ (transdermal))
In clinical studies of 104 patients treated with Testro AQ (Testro AQ (transdermal)), the most common adverse effects reported were local effects. In US clinical trials, most of the 72 patients filling out a daily questionnaire reported scrotal itching, discomfort, or irritation at some time during therapy. Of all the daily questionnaire responses, 7% reported itching, 4% discomfort, and 2% irritation. All topical reactions decreased with duration of use.
The following adverse effects (greater than 1%) were reported in association with Testro AQ (Testro AQ (transdermal)) therapy in 104 patients using the product for up to three years. These effects are listed in decreasing frequency of occurrence with the percentages of patients reporting the effect in parentheses: Gynecomastia (5%), acne (4%), prostatitis/urinary tract infection (4%), breast tenderness (3%), stroke (2%). For this same patient population, the following adverse effects were reported by 1% of users: memory loss, pupillary dilation, abnormal liver enzymes, scrotal cellulitis, deep vein phlebitis, benign prostatic hyperplasia, rectal mucosal lesion over prostate, hematuria/bladder cancer, papilloma on scrotum, and congestive heart failure.
Adverse Events with Testro AQ (Testro AQ (transdermal)) WITH ADHESIVE
In a pharmacokinetic study in 50 normal men, skin assessment scores following a single 24-hour application of Testro AQ (Testro AQ (transdermal)) WITH ADHESIVE to scrotal skin were similar to those for Testro AQ (Testro AQ (transdermal)). Other adverse events reported during the study were headache (6%), dizziness (6%), back pain, pain, nausea, and pustular rash (1% each).
General Adverse Events with Androgen Replacement Therapy
Skin and Appendages: Hirsutism, male pattern baldness, seborrhea, and acne.
Endocrine and Urogenital: Gynecomastia and excessive frequency and duration of penile erections. Oligospermia may occur at high doses.
Fluid and Electrolyte Disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.
Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests. Rare instances of hepatocellular neoplasms and peliosis hepatis have occurred.
Hematologic: Suppression of clotting factors II, V, VII, and X, bleeding in patients on concomitant anticoagulant therapy, and polycythemia.
Nervous System: Increased or decreased libido, headache, anxiety, depression, and generalized paresthesia.
Metabolic: Increased serum cholesterol.
Miscellaneous: Rarely, anaphylactoid reactions.
DRUG ABUSE AND DEPENDENCE
The Testro AQ (Testro AQ (transdermal)) products contain a Schedule III controlled substance as defined by the Anabolic Steroids Control Act.
Testro AQ (Testro AQ (transdermal)) TTS is designed for application to arm, back or upper buttocks skin.
Testro AQ (Testro AQ (transdermal)) and Testro AQ (Testro AQ (transdermal)) WITH ADHESIVE are designed for application to scrotal skin only. Because scrotal skin is at least five times more permeable to Testro AQ than other skin sites, Testro AQ (Testro AQ (transdermal)) or Testro AQ (Testro AQ (transdermal)) WITH ADHESIVE will not produce adequate serum Testro AQ concentrations if applied to non-scrotal skin.
Ingestion of Testro AQ, or the contents of any of the Testro AQ (Testro AQ (transdermal)) products will not result in clinically significant serum Testro AQ concentrations due to extensive first-pass metabolism. In addition, an intramuscular injection of Testro AQ from any of the Testro AQ (Testro AQ (transdermal)) products will not produce adequate serum Testro AQ levels due to its short half-life (about 10 minutes).
Testro AQ contraindications
See also:
What is the most important information I should know about Testro AQ?
-
Testro AQ Gel 1% is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate.
-
Testro AQ Gel 1% is contraindicated in women who are or may become pregnant, or who are breastfeeding. Testro AQ Gel 1% may cause fetal harm when administered to a pregnant woman. Testro AQ Gel 1% may cause serious adverse reactions in nursing infants. Exposure of a female fetus or nursing infant to androgens may result in varying degrees of virilization. Pregnant women or those who may become pregnant need to be aware of the potential for transfer of Testro AQ from men treated with Testro AQ Gel 1%. If a pregnant woman is exposed to Testro AQ Gel 1%, she should be apprised of the potential hazard to the fetus.
Active ingredient matches for Testro AQ:
List of Testro AQ substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Testoviron-Depot Paranova (Denmark) | |
| Testoviron-Depot-250 (Germany) | |
| Testovis (Italy) | |
| Testovital (Chile) | |
| Gel; Topical; Testosterone Micronized 1% | |
| Testovital 1% (Peru) | |
| Testoxyl | |
| Testozzard | |
| Testred Cypionate 200 | |
| Testred Injections | |
| Injectable; Injection; Testosterone Cypionate | |
| Testrex | |
| Testrin-P.A | |
| Testrin-P.A. | |
| Testro | |
| Testro-LA | |
| Testron Depot (Japan) | |
| Testrone | |
| Testryl | |
| Tostran (Czech Republic, Denmark, Germany, Hungary, Ireland, Netherlands, Norway, Poland, Switzerland, United Kingdom) | |
| Tostran 2% (Poland) | |
| Tostran 2% Gel (United Kingdom) | |
| Tostrelle | |
| Tostrex (Italy, South Korea) | |
| Tostrex 2 % x 60 g x 1's (Kalbe Farma) | |
| Tostrin | |
| Triolandren | |
| Undestor (Argentina, Bulgaria, Czech Republic, Poland, Romania, Slovakia, Sweden) | |
| Undestor Testocaps (Sweden) | |
| Uni-Test | |
| Injectable; Injection; Testosterone 100 mg / ml | |
| Uniteston | |
| Veto-Test | |
| Injectable; Injection; Testosterone 100 mg / ml | |
| Virigen (Denmark, Turkey) | |
| Virilisterona | |
| Virilon IM | |
| Virilon Injections | |
| Injectable; Injection; Testosterone Cypionate | |
| Virormone (Bahrain, Cyprus, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Oman, Qatar, Saudi Arabia, Syria, United Arab Emirates, United Kingdom, Yemen) | |
| Virosterone | |
| Vogelxo gel | |
| Vogelxo Pump | |
| Vulvan | |
| Xyosted | |
| Xyosted Injection | |
See 644 substitutes for Testro AQ | |
References
- DailyMed. "TESTOSTERONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "testosterone". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "testosterone". http://www.drugbank.ca/drugs/DB00624 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Testro AQ are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Testro AQ. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
